Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis

There was a significant dose-dependent increase in risk of proteinuria and hypertension in patients with cancer who received bevacizumab.